Inspur Launches New AI Servers to Support Latest NVIDIA A100 PCIe Gen 4 at ISC20
22.6.2020 10:07:00 EEST | Business Wire | Press release
Inspur, a leading data center and AI full-stack solutions provider, releases NF5468M6 and NF5468A5 AI servers supporting the latest NVIDIA A100 PCIe Gen 4 GPU at ISC High Performance 2020. It will provide AI users around the world with the ultimate AI computing platform with superior performance and flexibility.
Thanks to its agile and strong product design and development capabilities, Inspur is one of the first in the industry to support the NVIDIA A100 Tensor Core GPU and build up a comprehensive and competitive next-generation AI computing platform. The A100 GPU brings unprecedented versatility by accelerating a full range of precisions—from FP32 to FP16 to INT8 and all the way down to INT4. This includes the new TF32 precision, which works like FP32 while providing 20X higher FLOPS for AI without requiring any code change. In addition, the NVIDIA A100 offers multi-instance GPU technology, which enables a single GPU to be partitioned into seven hardware-isolated instances to work on multiple networks simultaneously. At present, Inspur’s two new products-NF5488M5-D and NF5488A5 with the NVIDIA A100 have taken the lead in mass production.
The newly released NF5468M6 and NF5468A5 present many innovative designs and strike a balance between superior performance and flexibility, which well meets increasingly complex and diverse AI computing needs. NF5468M6 and NF5468A5 can offer superb computing performance for high-performance computing and cloud application scenarios.
NF5468M6 and NF5468A5 accommodate eight double-width A100 PCIe cards in a 4U chassis. Both support the latest PCIe Gen4 of 64GB/s bi-directional bandwidth, delivering a 100% increase in bandwidth compared to PCIe Gen3 with the same power consumption. Its superior performance will meet the requirements of the most complex challenges in data science, high-performance computing, and artificial intelligence. Besides, 40GB of HBM2 memory increases memory bandwidth by 70% to 1.6TB/s, allowing users to train larger deep learning models. The unique NVIDIA NVLink bridge design can provide P2P performance of up to 600GB/s between two GPUs, resulting in significant increases in training efficiency
Furthermore, another two leading AI servers of Inspur, NF5468M5 and NF5280M5, also support NVIDIA A100 PCIe Gen 4.
As the world’s leading AI server manufacturer, Inspur offers an extensive range of AI products, and works closely with AI customers to improve AI application performance in different scenarios such as voice, semantic, image, video, and search.
About Inspur
Inspur is a leading provider of data center infrastructure, cloud computing, and AI solutions, ranking among the world’s top 3 server manufacturers. Through engineering and innovation, Inspur delivers cutting-edge computing hardware design and extensive product offerings to address important technology arenas like open computing, cloud data center, AI, and deep learning. Performance-optimized and purpose-built, our world-class solutions empower customers to tackle specific workloads and real-world challenges. To learn more, please go to www.inspursystems.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200622005207/en/
Contact information
Fiona Liu
Liuxuan01@inspur.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 02:56:00 EEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release
For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom